Elevation Oncology, Inc. (ELEV) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Boston, NY, 미국. 현재 CEO는 Joseph J. Ferra Jr..
ELEV 을(를) 보유 IPO 날짜 2021-06-25, 34 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $21.63M.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
